3B Pharmaceuticals GmbH news

Lausanne, Switzerland- March 25, 2020 - Debiopharm, a Swiss-based biopharmaceutical company announced today having entered into a worldwide, exclusive license & research agreement with 3B Pharmaceuticals (3BP), a German biotechnology firm, to further the development of their radioligand program, now called Debio 0228, which targets the CAIX (Carbonic Anhydrase 9) enzyme to fight the progression of cancer. This agreement extends the radio-oncology portfolio of Debiopharm which currently in

Program irom Jb rnarmaceuticais Clovis to acquire rights to discovery program for three additional targets for
radionuclide therapy

• Clovis to pay approximately $12 million in upfront payments to 3B Pharmaceuticals
• Clovis currently planning to file an IND for FAP-targeted radiopharmaceutical therapy in 2H 2020
• FAP highly expressed in multiple tumor types; Clovis to pursue broad and accelerated clinical development program

BOULDER, Colo, a